Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist: a patent evaluation of CA2958110 and IN6616DEN2012
- 16 July 2018
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 28 (10) , 723-727
Abstract
Introduction: Sleep apnoea syndrome (SAS), is a sleep disorder and characterized by very shallow breath or repetitive cessation of breathing during sleep (sleep apnoea). At present, no pharmacological agents have proved to be successful against SAS, and the syndrome is only treated by surgical interventions or devices such as intraoral mandibular advancement and Continuous Positive Air Pressure (CPAP) techniques. Areas covered: two patents published in 2016 describing a new pharmacological application of inhibitors of the metalloenzyme Carbonic Anhydrases (CAs, EC 4.2.1.1) and an aldosterone antagonist agents and their therapeutic application was analysed. Expert opinion: The present patents address an important healthcare problem by proposing a new pharmacological approach and may represent a valid alternative for the treatment of sleep apnea. One of the interesting points raised by these patents is the advantage of using a minor quantity of pharmacological agents in combination than active agent alone and consequently, a significant reduction of the side effects.Keywords
Funding Information
- funded
This publication has 28 references indexed in Scilit:
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese AdultsSLEEP, 2012
- Sulfonamides: a patent review (2008 – 2012)Expert Opinion on Therapeutic Patents, 2012
- Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesityExpert Opinion on Emerging Drugs, 2012
- Resistant hypertension, obstructive sleep apnoea and aldosteroneJournal of Human Hypertension, 2011
- Bacterial Carbonic Anhydrases as Drug Targets: Toward Novel Antibiotics?Frontiers in Pharmacology, 2011
- Carbonic anhydrases: novel therapeutic applications for inhibitors and activatorsNature Reviews Drug Discovery, 2008
- Sleep apnea: Clinical investigations in humansSleep Medicine, 2007
- Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ‘selective’ inhibitor celecoxibBioorganic & Medicinal Chemistry Letters, 2006
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- The Pittsburgh sleep quality index: A new instrument for psychiatric practice and researchPsychiatry Research, 1989